Literature DB >> 19063992

Targeted therapy for neuro-oncology: reviewing the menu.

Lois A Lampson1.   

Abstract

Targeted therapy against cancer shows not only promise, but also limits. No matter how specific the target, many pathways and cell types can be affected, some unexpectedly. A tumor is heterogeneous and plastic; it can evade a targeting agent or an attack mechanism. Local regulatory factors contribute to site-specific effects. In the brain, widely disseminated tumor, including microscopic tumor; local regulatory differences and impediments to brain-wide delivery can all limit the efficacy of any single agent or approach. Provocatively, precedents for both problems and solutions are seen in the original targeted therapy, the immune response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19063992     DOI: 10.1016/j.drudis.2008.11.003

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  2 in total

1.  Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles.

Authors:  Adam J Cole; Allan E David; Jianxin Wang; Craig J Galbán; Victor C Yang
Journal:  Biomaterials       Date:  2011-09       Impact factor: 12.479

Review 2.  Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier.

Authors:  Lois A Lampson
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.